LENZ Therapeutics, Inc.

NASDAQ:LENZ

Biotechnology

Healthcare
$3.34 -6.62%

-$0.42 today

Market cap
$104.94M
Beta
1.47
P/E (TTM)
-1.7
EPS (TTM)
-$3.48
52W Low $5.85High $50.40

Volume 0.64M

Average 0.89M

Income Statement

Follow revenue through to earnings.

Revenue

$19.09M

FY 2025 · Annual

Operating Income

-$91.14M

FY 2025 · Annual

Net Income

-$82.13M

FY 2025 · Annual

Income Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Revenue015M0019.09M
Cost of Revenue734K0058K705K
Gross Profit(734K)15M0(58K)18.38M
Gross Margin—100.0%——96.3%
Research & Development37.93M21.13M59.5M29.8M18.67M
Selling, General & Admin21.78M4.36M12.93M28.75M90.85M
Operating Expenses59.71M25.48M72.43M58.55M109.52M
Depreciation & Amortization734K8K15K58K287K
EBITDA(70.03M)(10.46M)(70.13M)(49.71M)(81.34M)
EBITDA Margin—-69.7%——-426.1%
Operating Income(60.44M)(10.48M)(72.43M)(58.61M)(91.14M)
Operating Margin—-69.9%——-477.5%
Interest Income002.19M8.55M9.76M
Interest Expense00000
Other Income / Expenses(10.32M)19K2.28M8.84M9.51M
Income Before Tax(70.76M)(10.46M)(70.15M)(49.77M)(81.63M)
Pre-Tax Margin—-69.8%——-427.6%
Income Tax Expense0347K(179K)1K502K
Net Income(70.76M)(10.81M)(69.97M)(49.77M)(82.13M)
Net Margin—-72.1%——-430.3%
EPS (Basic)(8.54)(12.89)(15.30)(2.34)(2.85)
EPS (Diluted)(8.54)(12.89)(15.30)(2.34)(2.85)
Weighted Avg Shares8.29M7.84M8.15M21.28M28.81M
Weighted Avg Shares (Diluted)8.29M7.84M8.15M21.28M28.81M

LENZ Earnings Waterfall · TTM

NASDAQ:LENZ · Revenue to Net Income

Key Ratios

EPS$-3.60
Gross Margin75.8%
Net Margin-1218.7%
P/E Ratio-9.7
P/S Ratio183.7

Analysis

$21.0M of revenue converted into -$109.0M of net income for the selected period. Gross margin is 75.8% and net margin is -1218.7%, showing how much revenue survives after costs and taxes. EPS is $-3.60, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 5, 2026
SC 13GSC 13G filingNov 4, 2026
4Statement of changes in beneficial ownershipNov 3, 2026
10-QQuarterly reportNov 3, 2026
4Statement of changes in beneficial ownershipNov 2, 2026

How much revenue does LENZ generate?

LENZ Therapeutics, Inc. (LENZ) reported $19.09M of revenue in fiscal 2025.

Is LENZ profitable?

LENZ Therapeutics, Inc. (LENZ) reported -$82.13M of net income, with a net margin of -430.3%.